TOPICOP©: a new scale evaluating topical corticosteroid phobia among atopic dermatitis outpatients and their parents

Leïla Moret, Emmanuelle Anthoine, Hélène Aubert-Wastiaux, Anne Le Rhun, Christophe Leux, Juliette Mazereeuw-Hautier, Jean-François Stalder, Sébastien Barbarot, Leïla Moret, Emmanuelle Anthoine, Hélène Aubert-Wastiaux, Anne Le Rhun, Christophe Leux, Juliette Mazereeuw-Hautier, Jean-François Stalder, Sébastien Barbarot

Abstract

Background: The fear of using topical corticosteroids, usually called topical corticophobia, is a frequent concern for atopic dermatitis patients and/or their parents. Assessing patients' atopic dermatitis and their parents' topical corticosteroid phobia is an essential step to improving adherence to treatment. Because topical corticophobia appears to be a complex phenomenon, its evaluation by binary responses (yes/no) is too simplistic. Thus, a scale is needed, which is capable of identifying the subtleties of topical corticosteroid phobia.

Objectives: To develop and validate a scale, TOPICOP©, measuring worries and beliefs about topical corticosteroids among atopic dermatitis outpatients and their parents.

Methods: An initial statistical validation of TOPICOP was carried out, collecting qualitative data about patients' topical corticophobia behaviors and beliefs using focus-group methodology. Then, 208 outpatients or their parents from five French centers completed a self-administered questionnaire built from focus-group results. The scale-development process comprised an explanatory principal component analysis, Cronbach's α-coefficients and structural equation modeling.

Results: The validated questionnaire comprised 12 items, covering two important dimensions relative to "worries" (6 items) and "beliefs" (6 items). Psychometric properties showed that items had very good communality (>0.60) within their own dimension. The final two-factor solution accounted for 47.3% of the variance. Cronbach's α-coefficients were, respectively, 0.79 and 0.78. Structural equation modeling strongly supported the possibility of calculating a global score.

Conclusions: TOPICOP© is the first scale aimed at assessing topical corticophobia in adult patients and parents of children with eczema. TOPICOP® has excellent psychometric properties and should be easy to use in everyday clinical practice for clinicians and researchers. Further studies are needed to confirm our results and validate TOPICOP© in other cultures.

Conflict of interest statement

Competing Interests: The authors have declared that no competing interests exist.

Figures

Figure 1. Selection process of items (flow…
Figure 1. Selection process of items (flow chart).
Figure 2. Structural equation model of the…
Figure 2. Structural equation model of the TOPICOP© scale.
Abbreviation: TCS, topical corticosteroids. Goodness-of-fit criteria: Steiger’s root mean square error of approximation = 0.005; Bentler and Bonnet’s normed fit index = 0.89; Goodness-of-fit index = 0.94.

References

    1. Williams HC, Burney PG, Pembroke AC, Hay RJ (1994) The U.K. Working Party’s Diagnostic Criteria for Atopic Dermatitis. III. Independent hospital validation. Br J Dermatol 131: 406–416.
    1. Lawson V, Lewis-Jones MS, Finlay AY, Reid P, Owens RG (1998) The family impact of childhood atopic dermatitis: the Dermatitis Family Impact Questionnaire. Br J Dermatol 138: 107–113.
    1. Kiebert G, Sorensen SV, Revicki D, Fagan SC, Doyle JJ, et al. (2002) Atopic dermatitis is associated with a decrement in health-related quality of life. Int J Dermatol 41: 151–158.
    1. Beattie PE, Lewis-Jones MS (2006) A comparative study of impairment of quality of life in children with skin disease and children with other chronic childhood diseases. Br J Dermatol 155: 145–151.
    1. Foley P, Zuo Y, Plunkett A, Marks R (2001) The frequency of common skin conditions in preschool-age children in Australia: atopic dermatitis. Arch Dermatol 137: 293–300.
    1. Carroll CL, Balkrishnan R, Feldman SR, Fleischer Jr AB, Manuel JC (2005) The burden of atopic dermatitis: impact on the patient, family, and society. Pediatr Dermatol 22: 192–199.
    1. Barbeau M, Bpharm HL (2006) Burden of Atopic dermatitis in Canada. Int J Dermatol 45: 31–36.
    1. Horii KA, Simon SD, Liu DY, Sharma V (2007) Atopic dermatitis in children in the United States, 1997–2004: visit trends, patient and provider characteristics, and prescribing patterns. Pediatrics 120: e527–34.
    1. McHenry PM, Williams HC, Bingham EA (1995) Management of atopic eczema. Joint Workshop of the British Association of Dermatologists and the Research Unit of the Royal College of Physicians of London. BMJ 310: 843–847.
    1. Hoare C, Li Wan Po A, Williams H (2000) Systematic review of treatments for atopic eczema. Health Technol Assess 4: 1–191.
    1. Charman CR, Morris AD, Williams HC (2000) Topical corticosteroid phobia in patients with atopic eczema. Br J Dermatol 142: 931–936.
    1. Hon KL, Kam WY, Leung TF, Lam MC, Wong KY, et al. (2006) Steroid fears in children with eczema. Acta Paediatr 95: 1451–1455.
    1. Ou HT, Feldman SR, Balkrishnan R (2010) Understanding and improving treatment adherence in pediatric patients. Semin Cutan Med Surg 29: 137–140.
    1. Krejci-Manwaring J, Tusa MG, Carroll C, Camacho F, Kaur M, et al. (2007) Stealth monitoring of adherence to topical medication: adherence is very poor in children with atopic dermatitis. J Am Acad Dermatol 56: 211–216.
    1. Aubert-Wastiaux H, Moret L, Le Rhun A, Fontenoy AM, Nguyen JM, et al... (2011) Topical corticosteroid phobia in atopic dermatitis: a study of its nature, origins and frequency. Br J Dermatol.
    1. Gosselin P, Dugas MJ, Ladouceur R, Freeston MH (2001) [Evaluation of worry: validation of a French translation of the Penn State Worry Questionnaire]. Encephale 27: 475–484.
    1. Pelletier O, Gosselin P, Langlois F, Ladouceur R (2002) [Study of psychometric properties of two new questionnaires assessing beliefs in hypochondriasis in a non-clinical population]. Encephale 28: 298–309.
    1. Kitzinger J (1995) Qualitative research. Introducing focus groups. BMJ 311: 299–302.
    1. Campbell DT, Fiske DW (1959) Convergent and discriminant validation by the multitrait-multimethod matrix. Psychol Bull 56: 81–105.
    1. Hoyle RH (1995) Structural equation modeling: concepts, issues and applications. Sage.
    1. Jöreskog KG (1970) A general method for analysis of covariance structure. Biometrika 57: 239–251.
    1. Anderson Gerbin, D.W JC (1984) The effect of sampling error on convergence, improper solutions, and goodness of fit indices for maximum likelihood confirmatory factor analysis. Psychometrika 49: 155–173.
    1. Coste J, Guillemin F, Pouchot J, Fermanian J (1997) Methodological approaches to shortening composite measurement scales. J Clin Epidemiol 50: 247–252.
    1. Cronbach LJ (1951) Coefficient alpha and the internal structure of tests. Psychometrika 16: 297–334.
    1. Nunnaly JC (1978) Psychometric Theory 2nd edition. New York. McGraw-Hill.
    1. David TJ (1987) Steroid scare. Arch Dis Child 62: 876–878.
    1. Patterson R, Walker CL, Greenberger PA, Sheridan EP (1989) Prednisonephobia. Allergy Proc 10: 423–428.
    1. Sterry W (1992) Therapy with topical corticosteroids. Arch Dermatol Res 284 Suppl : S27–9
    1. Diagnostic and statistical manual of mental disorders, ed. (1994). Washington D.C.: American Psychiatric Association.
    1. Gosselin P, Laberge B (2003) [Etiological factors of generalized anxiety disorder]. Encephale 29: 351–361.
    1. Fischer G (1996) Compliance problems in paediatric atopic eczema. The Australasian journal of dermatology 37 Suppl 1S10–3.
    1. Fukaya M (2000) Why do patients with atopic dermatitis refuse to apply topical corticosteroids? Dermatology 201: 242–245.
    1. Schmitt J, Williams H (2010) Harmonising Outcome Measures for Eczema (HOME). Report from the First International Consensus Meeting (HOME 1), 24 July 2010, Munich, Germany. The British journal of dermatology 163: 1166–1168.

Source: PubMed

Sponsorit ja yhteistyökumppanit

Sairaudet

Huumeiden interventiot

3
Tilaa